Actos (Pioglitazone) Bladder Cancer |
|
Actos Linked to Bladder Cancer![]() The following injuries or side effects have been reported by the FDA:
If you or someone you know took Actos or Zactos, it may be important to contact an attorney who can help you protect your potential legal claim. Monsour Law Firm is an experienced law firm helping patients and families. Actos News
New Warning for ActosIn September, the FDA launched a safety review of Actos after initial data from the manufacturers ongoing 10-year study suggested that the drug may increase the risk of bladder cancer. The agency says it is also aware of a recent epidemiological study in France that also suggests an increased risk of bladder cancer associated with Actos. Based on this study, France has suspended use of the drug and advised not starting Actos in new patients. Actos is part of a class of drugs known as thiazolidinediones that is used to treat type 2 diabetes. It is designed to help control blood sugar levels by increasing the bodys sensitivity to insulin. FDA AlertPossible signs/symptoms of bladder cancer from Actos may include: What is Actos (Pioglitazone)?Actos (Pioglitazone) is a prescription drug of the class thiazolidinedione (TZD) with hypoglycemic (antihyperglycemic, antidiabetic) action. Pioglitazone is marketed as trademarks Actos in the USA, the UK and Germany, Glustin in Europe,"Glizone" and "Pioz" in India by Zydus CND and USV respectively and Zactos in Mexico by Takeda Pharmaceuticals. Actos was the tenth-best selling drug in the U.S. in 2008, with sales exceeding $2.4 billion.[1] Its cardiovascular safety profile compares favorably with rosiglitazone (Avandia), which was withdrawn after concerns about an increased risk of cardiac events, but pioglitazone has subsequently been found to be associated with bladder tumors and has been withdrawn in some countries. FDA SAFETY WATCH ON Actos |